ClinicalTrials.gg
CompletedNCT00952341Updated Jun 2, 2017Results posted

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

A Phase 3 interventional study of aprepitant and Comparator: Placebo to aprepitant in Chemotherapy-induced Nausea and Vomiting (CINV), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
421
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.

Enrollment
6th of 61
421 · median 92
Started
2009
with 5 others
Phase 3
15 of 61
1 open now
Registered
21st of 61
by date
Lead sponsor
9 of 61
Merck Sharp & Dohme LLC

Among the 61 studies testing aprepitant in Vomiting, this one is the 6th largest by enrollment, is one of 6 that started in 2009, is one of 15 in phase 3, and was the 21st registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing aprepitant in Vomiting, or all of them as a file.
02

Study summary

This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.

03

Conditions studied

  • Chemotherapy-induced Nausea and Vomiting (CINV)

Browse trials for

Keywords

  • CINV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cycle 1:

  • Patient is scheduled to receive his/her first course of cisplatin chemotherapy at a dose of at least 70 mg/m\^2 administered a maximum of 3 hours
  • Patient has a predicted of at least 3 months
  • Patient is not pregnant

Cycle 2 (optional):

  • Participation in the study during the next cycle of chemotherapy is considered

appropriate by the investigator and will not pose unwarranted risk to the patient.

  • Satisfactory completion of the preceding cycle of chemotherapy and related

study procedures.

  • Patient will continue to receive the same chemotherapy regimen as in Cycle 1. The cisplatin dose may be reduced in subsequent cycle, as long as the new

dose is still no less than 70 mg/m\^2.

Exclusion criteria

Exclusion Criteria:

Cycles 1 \& 2:

  • Patient will receive stem cell therapy in conjunction with cisplatin
  • Patient has an active infection or any uncontrolled disease (e.g. diabetes)
  • Patient will receive multiple-day chemotherapy with cisplatin
  • Patient will receive chemotherapy of moderate or high emetogenicity on the 6 days prior to cisplatin infusion or the 6 days following the cisplatin infusion
  • Patient has vomited within 24 hours prior to cisplatin infusion
  • Patient received or will receive radiation therapy to the abdomen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
421 participants (actual)

Study arms

  • Experimental
    Aprepitant (MK-0869)

    Drug: aprepitant · Drug: granisetron · Drug: dexamethasone

  • Placebo comparator
    Standard Therapy

    Drug: Comparator: Placebo to aprepitant · Drug: dexamethasone · Drug: granisetron

Interventions

  • Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg

  • DrugComparator: Placebo to aprepitant

    Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg

  • Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg

  • Day 1: IV granisetron 3 mg prior to administration of cisplatin

  • Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1

    Overall phase was defined as 0 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.

    Time frame: 0 to 120 hours

Secondary outcomes

  1. Proportion of Participants With Complete Response in the Acute Phase of Cycle 1

    Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.

    Time frame: 0 to 24 hours

  2. Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1

    Delayed phase was defined as 25 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.

    Time frame: 25 to 120 hours

  3. Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1

    Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy. No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).

    Time frame: 0 to 120 hours

  4. Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1

    Acute Phase was defined as 0 to 24 hours following initiation of chemotherapy.

    Time frame: 0 to 24 hours

  5. Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1

    Delayed Phase was defined as 25 to 120 hours following initiation of chemotherapy

    Time frame: 25 to 120 hours

  6. Proportion of Participants With No Impact on Daily Life in Cycle 1

    The Functional Living Index-Emesis is a self-administered, validated emesis \& nausea-specific questionnaire. Participants completed the questionnaire 5 days post chemotherapy. It had 9 questions each on nausea and vomiting. "No impact of chemotherapy-induced nausea \& vomiting (CINV) on daily life" was defined as an average item score of \>6 on the 7-point scale (i.e., \>108 total score). The scale was in the opposite direction for questions 3, 6, 11, 15 \& 18. For each question: score ranged from 1 (worst) to 7 (best, i.e., no CINV). Total score range was 7 (worst) to 126 (best).

    Time frame: 0 to 120 hours

  7. Time to First Vomiting Episode in Cycle 1

    Time from administration of chemotherapy to first vomiting episode.

    Time frame: 0 to 120 hours

07

Results

Posted Sep 27, 2011

Participant flow

Cycle 1
Participant flow — Cycle 1
MilestoneAprepitant (MK-0869)Placebo
Started209212
Completed189199
Not completed2013
Withdrew: Adverse event41
Withdrew: Withdrawal by subject38
Withdrew: Protocol violation21
Withdrew: Lost to follow-up112
Withdrew: Physician decision01
Cycle 2
Participant flow — Cycle 2
MilestoneAprepitant (MK-0869)Placebo
Started110130
Completed101118
Not completed912
Withdrew: Withdrawal by subject11
Withdrew: Protocol violation10
Withdrew: Lost to follow-up69
Withdrew: Physician decision11
Withdrew: Progressive disease01

Outcome measures

PrimaryProportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1

Overall phase was defined as 0 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.

Time frame:
0 to 120 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 10.6960.570
Statistical analysis
  • Aprepitant (MK-0869) vs Placebo · Regression, Logistic · p = 0.007
SecondaryProportion of Participants With Complete Response in the Acute Phase of Cycle 1

Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.

Time frame:
0 to 24 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With Complete Response in the Acute Phase of Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With Complete Response in the Acute Phase of Cycle 10.7940.793
Statistical analysis
  • Aprepitant (MK-0869) vs Placebo · Regression, Logistic · p = 0.942
SecondaryProportion of Participants With Complete Response in the Delayed Phase of Cycle 1

Delayed phase was defined as 25 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.

Time frame:
25 to 120 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With Complete Response in the Delayed Phase of Cycle 10.7400.594
Statistical analysis
  • Aprepitant (MK-0869) vs Placebo · Regression, Logistic · p = 0.001
SecondaryProportion of Participants With No Vomiting in the Overall Phase of Cycle 1

Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy. No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).

Time frame:
0 to 120 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With No Vomiting in the Overall Phase of Cycle 10.7060.570
Statistical analysis
  • Aprepitant (MK-0869) vs Placebo · Regression, Logistic · p = 0.003
SecondaryProportion of Participants With No Vomiting in the Acute Phase of Cycle 1

Acute Phase was defined as 0 to 24 hours following initiation of chemotherapy.

Time frame:
0 to 24 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With No Vomiting in the Acute Phase of Cycle 10.8040.798
Statistical analysis
  • Aprepitant (MK-0869) vs Placebo · Regression, Logistic · p = 0.882
SecondaryProportion of Participants With No Vomiting in the Delayed Phase of Cycle 1

Delayed Phase was defined as 25 to 120 hours following initiation of chemotherapy

Time frame:
25 to 120 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 10.7400.594
Statistical analysis
  • Aprepitant (MK-0869) vs Placebo · Regression, Logistic · p = 0.001
SecondaryProportion of Participants With No Impact on Daily Life in Cycle 1

The Functional Living Index-Emesis is a self-administered, validated emesis \& nausea-specific questionnaire. Participants completed the questionnaire 5 days post chemotherapy. It had 9 questions each on nausea and vomiting. "No impact of chemotherapy-induced nausea \& vomiting (CINV) on daily life" was defined as an average item score of \>6 on the 7-point scale (i.e., \>108 total score). The scale was in the opposite direction for questions 3, 6, 11, 15 \& 18. For each question: score ranged from 1 (worst) to 7 (best, i.e., no CINV). Total score range was 7 (worst) to 126 (best).

Time frame:
0 to 120 hours
Reported as:
Number · Proportion of participants
Proportion of Participants With No Impact on Daily Life in Cycle 1
Proportion of participantsAprepitant (MK-0869)Placebo
Proportion of Participants With No Impact on Daily Life in Cycle 10.7050.683
SecondaryTime to First Vomiting Episode in Cycle 1

Time from administration of chemotherapy to first vomiting episode.

Time frame:
0 to 120 hours
Reported as:
Mean · Hours
Time to First Vomiting Episode in Cycle 1
HoursAprepitant (MK-0869)Placebo
Time to First Vomiting Episode in Cycle 177.0 ± 2.576.0 ± 2.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aprepitant (MK-0869), Cycle 1 & Cycle 2—5/205 (2.4%)123/205 (60%)
Placebo, Cycle 1 & Cycle 2—2/210 (1%)124/210 (59%)
Most frequent serious events
Most frequent serious events
EventAprepitant (MK-0869), Cycle 1 & Cycle 2Placebo, Cycle 1 & Cycle 2
DeathGeneral disorders1/2050/210
Lung infectionInfections and infestations1/2050/210
Neutrophil count decreasedInvestigations1/2051/210
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2050/210
Cerebral infarctionNervous system disorders1/2050/210
Febrile neutropeniaBlood and lymphatic system disorders0/2051/210
InfectionInfections and infestations0/2051/210
White blood cell count decreasedInvestigations0/2051/210
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAprepitant (MK-0869), Cycle 1 & Cycle 2Placebo, Cycle 1 & Cycle 2
White blood cell count decreasedInvestigations50/20549/210
Neutrophil count decreasedInvestigations33/20539/210
ConstipationGastrointestinal disorders38/20531/210
Decreased appetiteMetabolism and nutrition disorders30/20529/210
VomitingGastrointestinal disorders7/20529/210
NauseaGastrointestinal disorders12/20521/210
Alanine aminotransferase increasedInvestigations20/20521/210
Haemoglobin decreasedInvestigations15/20511/210
DiarrhoeaGastrointestinal disorders13/2058/210
FatigueGeneral disorders13/2054/210

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aprepitant (MK-0869)PlaceboTotal
Mean53.1 ± 10.153.6 ± 10.653.4 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Aprepitant (MK-0869)PlaceboTotal
Female7173144
Male138139277
Region of Enrollment
Region of Enrollment(participants)Aprepitant (MK-0869)PlaceboTotal
China209212421
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer. 2014 Apr;22(4):979-87. doi: 10.1007/s00520-013-2043-9. Epub 2013 Nov 26. PubMed 24276953 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Apr 2010, 7 months.

Results were first posted in Sep 2011, 1 year 5 months after primary completion. A results delay was requested in Apr 2011.

Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2009
First posted
Aug 6, 2009
StartActual
Aug 25, 2009
Primary completionActual
Apr 4, 2010
CompletionActual
May 5, 2010
Results delay requested
Apr 1, 2011
Results first posted
Sep 27, 2011
Last update
Jun 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00952341
Responsible party
Sponsor
First posted
Aug 6, 2009
Start date
Aug 25, 2009
Primary completion
Apr 4, 2010
Completion
May 5, 2010
Results posted
Sep 27, 2011
Last update
Jun 2, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion